Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip L Hooper

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Diabetes Care|March 1, 2003
Diabetes, nitric oxide, and heat shock proteinsPhilip L Hooper
Cell Stress & Chaperones|July 1, 2020
Correction to: COVID-19 and heme oxygenase: novel insight into the disease and potential therapiesPhilip L Hooper
Diabetes Technology & Therapeutics|April 29, 2005
Systemic diabetes mellitusPhilip L Hooper
Current Controlled Trials in Cardiovascular Medicine|January 25, 2002
Hypothesis to explain poor outcomes in the ALLHAT and V-HeFT trials: decreased expression of heat shock proteinsPhilip L Hooper
Cell Stress & Chaperones|November 30, 2021
Heme oxygenase agonists-fluvoxamine, melatonin-are efficacious therapy for Covid-19Philip L Hooper
Cell Stress & Chaperones|June 6, 2020
COVID-19 and heme oxygenase: novel insight into the disease and potential therapiesPhilip L Hooper
Metabolic Syndrome and Related Disorders|March 29, 2008
Insulin Signaling, GSK-3, Heat Shock Proteins and the Natural History of Type 2 Diabetes Mellitus: A HypothesisPhilip L Hooper
Ebiomedicine|July 3, 2015
Induction of Heat Shock Proteins in the Therapy of Type 2 Diabetes and Metabolic SyndromePhilip L Hooper
Cell Stress & Chaperones|May 9, 2022
Attenuation of exercise conditioning by metformin-a consequence of HSF1 inhibitionPhilip L Hooper
Hypertension (Dallas, Tex. : 1979)|February 6, 2004
Is low-heat shock protein 70 a primary or a secondary event in the development of atherosclerosis?Philip L Hooper, Joanna J Hooper
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Diabetes Care|March 1, 2003
Diabetes, nitric oxide, and heat shock proteinsPhilip L Hooper
Cell Stress & Chaperones|July 1, 2020
Correction to: COVID-19 and heme oxygenase: novel insight into the disease and potential therapiesPhilip L Hooper
Diabetes Technology & Therapeutics|April 29, 2005
Systemic diabetes mellitusPhilip L Hooper
Current Controlled Trials in Cardiovascular Medicine|January 25, 2002
Hypothesis to explain poor outcomes in the ALLHAT and V-HeFT trials: decreased expression of heat shock proteinsPhilip L Hooper
Cell Stress & Chaperones|November 30, 2021
Heme oxygenase agonists-fluvoxamine, melatonin-are efficacious therapy for Covid-19Philip L Hooper
Cell Stress & Chaperones|June 6, 2020
COVID-19 and heme oxygenase: novel insight into the disease and potential therapiesPhilip L Hooper
Metabolic Syndrome and Related Disorders|March 29, 2008
Insulin Signaling, GSK-3, Heat Shock Proteins and the Natural History of Type 2 Diabetes Mellitus: A HypothesisPhilip L Hooper
Ebiomedicine|July 3, 2015
Induction of Heat Shock Proteins in the Therapy of Type 2 Diabetes and Metabolic SyndromePhilip L Hooper
Cell Stress & Chaperones|May 9, 2022
Attenuation of exercise conditioning by metformin-a consequence of HSF1 inhibitionPhilip L Hooper
Hypertension (Dallas, Tex. : 1979)|February 6, 2004
Is low-heat shock protein 70 a primary or a secondary event in the development of atherosclerosis?Philip L Hooper, Joanna J Hooper
Pageof 5